Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Masonic Cancer Center, University of Minnesota
Primary Objective:
* To estimate the proportion of patients with donor derived engraftment at day 100 post transplant as defined by 80% or greater donor cells in the CD3 (T cell) fraction
Secondary Objectives:
* To determine the incidence and severity of graft-versus-host disease (GVHD) by day 100
* To determine the incidence of peri-transplant mortality (death by day 100)
* To monitor donor cell chimerism at various time points following allogeneic transplantation with this transplant regimen as determined at day 28, 42, 100, 6 months and yearly for 5 years.
Age
0–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have diagnosis of one of the following: mucopolysaccharidosis disorder, glycoprotein metabolic disorder, sphingolipidoses or inherited leukodystrophy, peroxisomal disorder or other inherited diseases of metabolism
Must have an acceptable graft source as defined by University of Minnesota criteria
Adequate organ function
You may not be if
Pregnant - menstruating females must have a negative serum pregnancy test within 14 days of treatment start
Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology